 | Purchase deal with firms only after Covid-19 vaccines prove effective: CentreAt present, vaccine candidates by Bharat Biotech, Serum Institute of India (Oxford University-AstraZeneca), and Zydus Cadila are under advanced stages of trials. |
 | If everything goes well India would get COVID-19 vaccine by year-end: Harsh VardhanThree COVID-19 vaccine candidates, including two indigenous ones, are in different phases of development in India. |
 | COVID-19: Zydus Cadila launches least expensive version on Remdesivir in IndiaThe drug will be made available across India through the group’s strong distribution chain reaching out to government and private hospitals treating Covid patients, announced Zydus. |
 | Zydus Cadila launches COVID-19 drug Remdesivir in India under brand name RemdacPriced at Rs 2,800 per 100 mg vial, Remdac is the most economical Remdesivir brand in India, Zydus Cadila said in a regulatory filing. |
 | ICMR says two COVID-19 vaccines on phase 2 trial now but researchers differPrincipal Investigators involved in the vaccine trial said that it will take at least a month for the first phase of the trial to be completed. |
 | Seven Indian pharma players race to develop COVID-19 vaccineLeading vaccine major Serum Institute of India has said that it is hoping to develop a COVID-19 vaccine by the year-end. |
 | Zydus Cadila gets USFDA nod to market generic tension headache tabletsThe company has received final approval to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement. |
 | Zydus Cadila begins human clinical trials of COVID-19 vaccine candidateIn the phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it said in a regulatory filing. |
 | Zydus Cadila gets approval from Mexican authority to test COVID-19 drug DesidustatThe company said it will conduct a study to evaluate the efficacy and safety of Desidustat tablets for the management of COVID-19 patients. |
 | Scientists strike note of caution as 'Made in India' vaccine programme gains momentumPhase 1 trials are small-scale, usually involving few participants, to assess whether the vaccine is safe for humans. |
| After Covaxin, DCGI nod to human trials for potential Covid-19 vaccine by Zydus-CadillaICMR DG Dr Balram Bhargava said that the subject enrollment should be completed by July 7 as the government is looking to launch the vaccine by August 15. |
